ArticleThe Lancet regional health. Europe2021

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.

Amir I Tukhvatulin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.